Literature DB >> 31326318

Biomarkers and early treatment of idiopathic pulmonary fibrosis.

Jonathan A Kropski1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31326318      PMCID: PMC6839826          DOI: 10.1016/S2213-2600(19)30256-5

Source DB:  PubMed          Journal:  Lancet Respir Med        ISSN: 2213-2600            Impact factor:   30.700


× No keyword cloud information.
  10 in total

1.  Safety, tolerability, pharmacokinetics, and pharmacodynamics of GLPG1690, a novel autotaxin inhibitor, to treat idiopathic pulmonary fibrosis (FLORA): a phase 2a randomised placebo-controlled trial.

Authors:  Toby M Maher; Ellen M van der Aar; Olivier Van de Steen; Lisa Allamassey; Julie Desrivot; Sonia Dupont; Liesbeth Fagard; Paul Ford; Ann Fieuw; Wim Wuyts
Journal:  Lancet Respir Med       Date:  2018-05-20       Impact factor: 30.700

2.  Current Status and Future Opportunities in Lung Precision Medicine Research with a Focus on Biomarkers. An American Thoracic Society/National Heart, Lung, and Blood Institute Research Statement.

Authors:  Ann Chen Wu; James P Kiley; Patricia J Noel; Shashi Amur; Esteban G Burchard; John P Clancy; Joshua Galanter; Maki Inada; Tiffanie K Jones; Jonathan A Kropski; James E Loyd; Lawrence M Nogee; Benjamin A Raby; Angela J Rogers; David A Schwartz; Don D Sin; Avrum Spira; Scott T Weiss; Lisa R Young; Blanca E Himes
Journal:  Am J Respir Crit Care Med       Date:  2018-12-15       Impact factor: 21.405

3.  Efficacy of pirfenidone in patients with idiopathic pulmonary fibrosis with more preserved lung function.

Authors:  Carlo Albera; Ulrich Costabel; Elizabeth A Fagan; Marilyn K Glassberg; Eduard Gorina; Lisa Lancaster; David J Lederer; Steven D Nathan; Dominique Spirig; Jeff J Swigris
Journal:  Eur Respir J       Date:  2016-07-28       Impact factor: 16.671

4.  Efficacy of Nintedanib in Idiopathic Pulmonary Fibrosis across Prespecified Subgroups in INPULSIS.

Authors:  Ulrich Costabel; Yoshikazu Inoue; Luca Richeldi; Harold R Collard; Inga Tschoepe; Susanne Stowasser; Arata Azuma
Journal:  Am J Respir Crit Care Med       Date:  2016-01-15       Impact factor: 21.405

5.  Prognostic and predictive biomarkers for patients with idiopathic pulmonary fibrosis treated with pirfenidone: post-hoc assessment of the CAPACITY and ASCEND trials.

Authors:  Margaret Neighbors; Christopher R Cabanski; Thirumalai R Ramalingam; X Rebecca Sheng; Gaik W Tew; Chunyan Gu; Guiquan Jia; Kun Peng; Jill M Ray; Brett Ley; Paul J Wolters; Harold R Collard; Joseph R Arron
Journal:  Lancet Respir Med       Date:  2018-06-29       Impact factor: 30.700

6.  Lung function outcomes in the INPULSIS® trials of nintedanib in idiopathic pulmonary fibrosis.

Authors:  Kevin K Brown; Kevin R Flaherty; Vincent Cottin; Ganesh Raghu; Yoshikazu Inoue; Arata Azuma; John T Huggins; Luca Richeldi; Susanne Stowasser; Wibke Stansen; Rozsa Schlenker-Herceg; Toby M Maher; Athol U Wells
Journal:  Respir Med       Date:  2018-11-19       Impact factor: 3.415

7.  A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.

Authors:  Talmadge E King; Williamson Z Bradford; Socorro Castro-Bernardini; Elizabeth A Fagan; Ian Glaspole; Marilyn K Glassberg; Eduard Gorina; Peter M Hopkins; David Kardatzke; Lisa Lancaster; David J Lederer; Steven D Nathan; Carlos A Pereira; Steven A Sahn; Robert Sussman; Jeffrey J Swigris; Paul W Noble
Journal:  N Engl J Med       Date:  2014-05-18       Impact factor: 91.245

8.  Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis.

Authors:  Luca Richeldi; Roland M du Bois; Ganesh Raghu; Arata Azuma; Kevin K Brown; Ulrich Costabel; Vincent Cottin; Kevin R Flaherty; David M Hansell; Yoshikazu Inoue; Dong Soon Kim; Martin Kolb; Andrew G Nicholson; Paul W Noble; Moisés Selman; Hiroyuki Taniguchi; Michèle Brun; Florence Le Maulf; Mannaïg Girard; Susanne Stowasser; Rozsa Schlenker-Herceg; Bernd Disse; Harold R Collard
Journal:  N Engl J Med       Date:  2014-05-18       Impact factor: 91.245

9.  Longitudinal change in collagen degradation biomarkers in idiopathic pulmonary fibrosis: an analysis from the prospective, multicentre PROFILE study.

Authors:  R Gisli Jenkins; Juliet K Simpson; Gauri Saini; Jane H Bentley; Anne-Marie Russell; Rebecca Braybrooke; Philip L Molyneaux; Tricia M McKeever; Athol U Wells; Aiden Flynn; Richard B Hubbard; Diana J Leeming; Richard P Marshall; Morten A Karsdal; Pauline T Lukey; Toby M Maher
Journal:  Lancet Respir Med       Date:  2015-03-12       Impact factor: 30.700

10.  Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline.

Authors:  Ganesh Raghu; Martine Remy-Jardin; Jeffrey L Myers; Luca Richeldi; Christopher J Ryerson; David J Lederer; Juergen Behr; Vincent Cottin; Sonye K Danoff; Ferran Morell; Kevin R Flaherty; Athol Wells; Fernando J Martinez; Arata Azuma; Thomas J Bice; Demosthenes Bouros; Kevin K Brown; Harold R Collard; Abhijit Duggal; Liam Galvin; Yoshikazu Inoue; R Gisli Jenkins; Takeshi Johkoh; Ella A Kazerooni; Masanori Kitaichi; Shandra L Knight; George Mansour; Andrew G Nicholson; Sudhakar N J Pipavath; Ivette Buendía-Roldán; Moisés Selman; William D Travis; Simon Walsh; Kevin C Wilson
Journal:  Am J Respir Crit Care Med       Date:  2018-09-01       Impact factor: 21.405

  10 in total
  2 in total

1.  Screening for idiopathic pulmonary fibrosis using comorbidity signatures in electronic health records.

Authors:  Dmytro Onishchenko; Robert J Marlowe; Che G Ngufor; Louis J Faust; Andrew H Limper; Gary M Hunninghake; Fernando J Martinez; Ishanu Chattopadhyay
Journal:  Nat Med       Date:  2022-09-29       Impact factor: 87.241

2.  CDKN2B antisense RNA 1 expression alleviates idiopathic pulmonary fibrosis by functioning as a competing endogenouse RNA through the miR-199a-5p/Sestrin-2 axis.

Authors:  Mei Yang; Egao Yin; Yiheng Xu; Yongjun Liu; Ting Li; Zhaoxing Dong; Wenlin Tai
Journal:  Bioengineered       Date:  2022-03       Impact factor: 6.832

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.